Eli Lilly and Co

Eli Lilly and Co

LLY - NEW YORK STOCK EXCHANGE, INC.

Industry: Pharmaceuticals

Market Cap: 751.6 B

IPO Date: Jul 9, 1970

Country: US

Currency: USD

Shares Outstanding: 947.7 M

GLP-1 Agonists Drug Pipeline Analysis Market Report 2025 | Next-generation GLP-1 Agonists Pave the Way for Diabetes and Obesity Management

7/14/2025

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18, offering both glycemic control and weight loss benefits. Key players such as Eli Lilly innovate, contributing to market expansion and investment in metabolic health.Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The "GLP-1 Agonists Drug Pipeline Analysis Report 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.The GLP-1 Agonists

News

Source: Yahoo

Obesity Drug Pipeline Analysis Report 2025 | Pfizer and Eli Lilly Lead the Charge in Cutting-Edge Obesity Research

7/14/2025

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite control and metabolic pathways, with pharmaceutical support bolstering development. The 2025 Obesity Drug Pipeline Report offers insights into recent breakthroughs, clinical trials, and regulatory trends, highlighting the shift toward personalized therapies and novel drug classes like peptides and RNA-based treatments. Key players include Pfizer and Eli L

News

Source: Yahoo

Biotech Stocks Are Ready to Rebound. 3 to Watch Now.

7/14/2025

Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed strength. Large pharmaceutical companies, facing thinning pipelines, are aggressively acquiring cutting-edge biotech firms. Notable billion-dollar deals in the past two months include the acquisition of Verona Pharma by Merck, Sanofi’s  buyout of Blueprint Medicines and Eli Lilly’s  purchase of Verve Therapeutics In a significant technical move, the ETF has recently broken out above an eight-month trend of lower highs—an important shift dating back to the start of the current administration.

News

Source: Yahoo

Trump Says 200% Pharma Tariffs Are Coming. Wall Street Shrugs.

7/13/2025

A generous grace period would give drugmakers time to sidestep most of the pain of looming duties.

News

Source: Yahoo

Why Novartis Is Still A 'Buy' After 15% Surge

7/13/2025

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks. Find out why NVS stock is a buy.

News

Source: SeekingAlpha

Novo Nordisk A/S (NVO): “Canada’s A Backdoor,” Says Jim Cramer

7/12/2025

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer recently discussed. Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical company that was one of the earliest movers in the weight loss drug market. The shares have lost 21% […]

News

Source: Yahoo

Eli Lilly and Company (LLY): I Would “Love” If Trump Praised The Company, Says Jim Cramer

7/12/2025

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company (NYSE:LLY) is one of the most frequently discussed pharmaceutical stocks on Cramer’s morning show. Over the course of this year, the CNBC […]

News

Source: Yahoo

FDA willing to trade faster drug reviews for lower prices, Bloomberg reports

7/12/2025

FDA Commissioner Marty Makary said the agency may fast-track new drugs from pharmaceutical companies that “equalize” the cost of their medicines between the U.S. and other countries, Bloomberg’s Rachel Cohrs Zhang and Sam Hornblower report. Makary said in an interview on Bloomberg Television’s Wall Street Week with David Westin that companies that promise to equalize prices can receive a “national priority review voucher,” which would cut review times to one to two months. The vouchers are part

News

Source: Yahoo

Big pharma's multiple looming patent cliffs: What to know

7/11/2025

The pharmaceutical industry is staring down a major patent cliff, with key drugs from Merck (MRK), Bristol Myers Squibb (BMY), and Johnson & Johnson (JNJ) set to lose exclusivity by 2030. Yahoo Finance Senior Reporter Anjalee Khemlani and Freedom Capital Markets chief global strategist Jay Woods join Market Domination host Josh Lipton to discuss the industry's risks and how Wall Street is responding. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

News

Source: Yahoo

Wall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth

7/11/2025

Eli Lilly Surges Ahead: JPMorgan Sees $1,100 Price Target on Obesity Drug Boom

News

Source: Yahoo

Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?

7/11/2025

LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.

News

Source: Yahoo

CGDV: Buy For Value, Stay For Dividend Growth

7/11/2025

News

Source: SeekingAlpha

Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts

7/11/2025

Terns' late-stage assets target CML & obesity with key data in Q4 2025. Explore their potential in massive markets. Click here to find out why TERN is a Buy.

News

Source: SeekingAlpha

Novo Nordisk: The Market Doesn't Get It

7/11/2025

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to read an analysis of NVO stock now.

News

Source: SeekingAlpha

Eli Lilly and : Our 2024 Sustainability Report PDF (2024 SustainabilityReport Final)

7/11/2025

2024 Sustainability Report Table of Contents A Message from Our CEO 3 Sustainability Highlights 4 Our Strategy ...

News

Source: Finnhub

Psoriatic Arthritis Market Report 2025-2035 | Competitive Analysis of AbbVie, UCB, Pfizer, Johnson & Johnson, Eli Lilly and Co, Bristol-Myers Squibb, Affibody, Amgen, Boehringer Ingelheim, Sun Pharma

7/11/2025

Psoriatic arthritis is a chronic inflammatory disease linked to psoriasis, characterized by joint inflammation, pain, and swelling. Affecting both men and women, typically between ages 30-50, it's driven by rising autoimmune diseases and emerging biologic treatments like TNF and JAK inhibitors. Key market developments include advances in early diagnosis tools and precision medicine, tailoring treatments to genetic profiles. While growth is challenged by high biologic costs and diagnosis complexi

News

Source: Yahoo

Eli Lilly Has Seized the Lead in Anti-Obesity Drugs. Next Up: a Pill.

7/11/2025

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

News

Source: Yahoo

FDRR: Look At FCPI Instead

7/11/2025

FDRR focuses on large-cap dividend stocks tied to Treasury yields but has lagged peers like FCPI despite solid dividend growth. Check out why FDRR ETF is a hold.

News

Source: SeekingAlpha

Eli Lilly and Co (India) with Association of Physicians of India announces launch of API - Obesity Gurukul - statement

7/11/2025

Eli Lilly and Co:* Eli Lilly and Co with Association of Physicians of India announces launch of API - Obesity Gurukul - statement...

News

Source: Finnhub

Integer Appoints Michael Coyle to Board of Directors

7/10/2025

~ New Director Brings Extensive Medical Device Industry Leadership and Technology Experience to Integer Board ~ PLANO, Texas, July 10, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced it has appointed Michael Coyle to its Board of Directors. Coyle brings more than 40 years of leadership in the medical device industry to Integer and joins the Board as a member of the Audi

News

Source: Yahoo